BRCA1 and neoplasm: When PARP inhibitors are used upon an existing BRCA1/2 mutation, DNA repair in tumor cells is further limited, thereby resulting in lethality, i.e., the “synthetic lethality” phenomenon, which is the treatment principle of PARP inhibitors (56).